Introduction
Organic anion transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1 belong to the superfamily of solute carrier transporters and mediate the membrane uptake of a wide range of clinically relevant drugs from the portal blood into hepatocytes (Giacomini et al., 2010; Niemi et al., 2011) . OATP1B1 has been highlighted as one of the most clinically relevant hepatic uptake transporter. Genetic polymorphism in the SLCO1B1 gene and drug-drug interactions (DDI) associated with this transporter, often coupled with metabolic interaction, raise efficacy and safety concerns (Gertz et al., 2013; Shitara et al., 2013; Gertz et al., 2014; Prueksaritanont et al., 2014; Tsamandouras et al., 2014 ) .
Recommendations regarding in vitro transporter assays and modeling approaches for the prediction of transporter-mediated pharmacokinetics and corresponding DDIs have been recently reviewed by the International Transporter Consortium (Zamek-Gliszczynski et al., 2013) . Despite advances in characterization of active uptake in vitro and consideration of mechanistic modelling of such data (Poirier et al., 2009; Menochet et al., 2012a) , a tendency to under-predict transportermediated hepatic clearance is often observed. This under-prediction trend (on average 17-to 58-fold) was evident across different cellular systems used to generate in vitro transporter data for the comparable drug set (Poirier et al., 2009; Jones et al., 2012; Menochet et al., 2012b) . To bridge this gap in the in vitro-in vivo extrapolation (IVIVE), clinical plasma concentration-time data have been used to optimize active uptake clearance in physiologically-based pharmacokinetic (PBPK) models, requiring an empirical scaling factor (ESF) for this parameter (Zamek-Gliszczynski et al., 2013; Gertz et al., 2014) . The concerning issue is that the extent of under-prediction and reported ESFs show drug-and donor-dependent differences and large variability depending on the hepatocyte format used and assumptions made in the optimization routine (Poirier et al., 2009; Watanabe et al., 2009; Gardiner and Paine, 2011; Jones et al., 2012; Menochet et al., 2012b; Gertz et al., 2014) . So far, transporter IVIVE of hepatocyte data generally does not account for any potential differences in the transporter expression between the tissue and the actual cellular system used, which may contribute to this under-prediction trend observed. In the case of OATP transfected cell lines, attempts have been made to account for expression differences in the form of relative expression factors (Hirano et al., 2004; Jamei et al., 2014) . However, these are often based on Western blot measurements and This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 6, 2015 as DOI: 10.1124/dmd.114.062034 at ASPET Journals on May 28, 2017 dmd.aspetjournals.org Downloaded from account for expression differences between transfected cell line and hepatocytes (based usually on a small number of donors) (Hirano et al., 2004) , rather than the actual liver tissue.
Recently, an increasing number of studies have reported the quantitative expression data for OATP1B1, OATP1B3 and OATP2B1 in human liver tissue and in some of the most commonly used in vitro cellular systems. It is evident that protein extraction and quantification methods used to obtain abundance data vary across systems together with procurement conditions, storage of tissue samples and demographic of the subjects. Most of the proteomic transporter expression studies are based on a relatively small number of subjects, with the exception of the recent study (Prasad et al., 2014) .
However, systematic analysis of such data and understanding of the magnitude of differences in the OATP expression levels between liver tissue and cellular systems is currently lacking.
The aim of the current work was to collate reported OATP expression data in human liver tissue and cellular systems, namely sandwich cultured hepatocytes (SCHH) and cryopreserved hepatocytes in suspension. Meta-analysis approach was performed to address the issues raised above and overcome the limitations of the individual studies in order to provide a reliable assessment of differences in OATP expression levels between liver tissues and hepatocytes systems. Based on the relevant eligible studies, critical outcomes such as the average abundance and variability of OATP1B1, OATP1B3 and OATP2B1 transporters abundance in liver tissue and in in vitro cellular systems, as well as the heterogeneity between studies, have been defined. In addition, correlations between individual transporter expression levels in liver tissue and the impact of demographic factors (including age and sex) were investigated. Implications of the integration of OATP abundance as relative expression factors in PBPK models to improve IVIVE of transporter-mediated drug disposition are discussed.
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Materials and Methods
Literature Search Strategy and Study Eligibility. Relevant published articles on the abundance data of OATP1B1, OATP1B3 and OATP2B1 transporters were searched through the electronic database MEDLINE using the following keyword combinations (hepatic/liver OATP transporter abundance, correlation of expression, quantification). The following criteria were applied for the inclusion of the studies in the analysis (i) simultaneous measurement OATP1B1, OATP1B3 and OATP2B1 abundance in the same individuals, (ii) use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) proteomic methods, (iii) reported abundance levels for the transporters of interest in human liver tissue or in vitro cellular systems and (iv) the abundance data based on quantification of total membrane protein (rather than plasma membrane) expression levels of the investigated OATP transporters. Individual abundance data were extracted from the collated studies.
If data were not quoted, GetData Graph Digitizer version 2.25 (http://getdata-graph-digitizer.com/) was utilized to digitize and extract the data. Donor demographics (including age and sex) were also collated where data were available. Studies with reported abundance data for the investigated transporters based on immunoblotting techniques, reported as plasma membrane protein measurement and/or reported in relative or arbitrary units were excluded.
Weighted Means and Coefficients of Variation Calculations.
Normality of distribution and homoscedasticity were assessed for expression data per individual transporter. The KolmogorovSmirnov test was conducted to determine the normality of distribution of abundance data. BrownForsythe Levene-type test was applied to examine the homogeneity of variances of collated expression data. Individual abundance levels expressed in liver tissue and in each in vitro cellular system were combined from the collected studies in order to generate weighted mean (W ഥ ) and weighted coefficient of variation (WCV) per individual transporter (Equations 1 and 2).
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where subscript j indicates the study j, n j the sample size of study j and ܺ ത j the mean abundance of a singular OATP transporter in study j.
Assessment of Heterogeneity between Studies. Cochran X 2 -based Q test and I 2 statistic (Higgins and Thompson test) were performed to define the between-study heterogeneity (Cochran, 1954; Higgins and Thompson, 2002; Higgins et al., 2003) , where a higher value of Cochran's heterogeneity statistic Q of the collated data indicates greater heterogeneity. The I 2 heterogeneity index is an indicator of the fraction of the variability due to true between-study differences. These calculations were based on Equations 3, 4 and 5. I 2 values of 25%, 50%, and 75% reflect evidence of low, moderate, and high heterogeneity, respectively. Probabilities were quoted based on X 2 distribution of the Q value and the number of degrees of freedom, k-1. Probability values were symbolized by: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, p-values of p < 0.05 were considered statistically significant.
where (VarWܺ ത ) represents the variance in the weighted mean of the collated data, sd j the standard deviation of study j and k the number of studies.
Comparison of Abundance Levels of OATP Transporters in In Vitro Cellular Systems
Relative to Liver Tissue. A non-parametric Kruskal-Wallis one-way analysis of variance (ANOVA) was conducted to assess any potential significant differences in abundance levels of OATP 
where Z represents the test statistic value and N the total number of samples.
Analogously, hepatic tissue expression of OATPs was analyzed by performing a KruskalWallis one-way analysis of variance (ANOVA) followed by a Mann-Whitney rank order U-test multiple comparisons to identify any potential inter-study differences. Bonferroni correction was applied to adjust the level of significance for the pairwise comparisons performed on a single set of data.
Probability values are symbolized by: * = p < 0.0125, ** = p < 0.0025, *** = p < 0.00025, where p < 0.0125 was considered statistically significant.
Assessment of Potential Correlation in Expression Levels of OATP Transporters in the
Same Individuals. Correlations between the hepatic tissue expression levels of OATP1B1, OATP1B3 and OATP2B1 were investigated using the non-parametric Spearman rank correlation test (Armitage, 2001) . The Spearman rank coefficient of correlation (Rs) and the probabilities (p) were calculated for each correlation test. Collated abundance data were normalized beforehand using the mean values of reference studies (Equation 7). Bonferroni correction was applied to adjust the level of significance for the pairwise comparisons performed on a single set of data. Probability values were symbolized by: * = p < 0.025, ** = p < 0.005, *** = p < 0.0005 and p < 0.025 was considered statistically significant.
‫ݔ‬ ҧ
reference the mean abundance in the reference study used for the normalization process. The weighted means and the reference abundance values used for data normalization are shown in Table 2 .
Investigation of Age-and Sex-Related Differences in Hepatic Tissue Expression Levels of OATP Transporters. Age-and sex-related differences in hepatic tissue expression data were assessed per individual OATP transporter. A Mann-Whitney rank order U-test was carried out to establish any potential differences between male and female subjects. Probability values are symbolized by: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, where p < 0.05 was considered statistically significant. In addition, a non-parametric Spearman rank correlation test was performed to investigate any potential correlation of transporters expression data with age of the human donors. The correlations were tested for the collated data. Probability values were symbolized by: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, where p < 0.05 was considered statistically significant.
This article has not been copyedited and formatted. The final version may differ from this version. (two studies) and in cryopreserved human hepatocytes in suspension (five studies). Individual protein expression levels were not reported in some of the selected studies and mean data were quoted in two studies. In three studies, the expression levels of OATP transporters were measured in only one sample, as outlined in Table 1 . Details of sample preparation and LC-MS/MS quantification used in the studies included in the meta-analysis are shown in Supplemental Table 2 .
Comparison of Abundance Levels of OATP Transporters in In Vitro Cellular Systems
Relative to Liver Tissue. OATP1B1 was identified as the most abundant uptake transporter with 5.9 ± 8.3, 5.8 ± 3.3 and 4.2 ± 1.7 fmol/μg protein in liver tissue, SCHH and cryopreserved suspended human hepatocytes, respectively ( Table 2 ). The rank order in average expression in liver tissue and in vitro cellular systems was OATP1B1 > OATP1B3 ≈ OATP2B1. Surprisingly, relative expression factors for all the OATPs investigated did not exceed 2.5. On average, OATP1B1 expression in the liver tissue was 1.4-fold greater in comparison to cryopreserved hepatocytes in suspension, whereas abundance of this transporter in SCHH (based on n=5) was comparable to the mean expression data in the liver tissue, suggesting no requirement for abundance corrections (relative expression factor=1). Mean OATP1B1 expression in human liver tissue was 3-fold greater than OATP1B3 and OATP2B1. The relative OATP1B1: OATP1B3 expression was higher compared to data reported by the Western blot measurements in 46 livers (1.6-fold difference) (Michalski et al., 2002) . Similar trends were seen in expression of OATP1B1 relative to other OATPs in cryopreserved hepatocytes. In contrast, expression of OATP1B1 was up to 7-fold higher in SCHH relative to OATP1B3 and OATP2B1 in the same system ( (Table 2) .
To assess the within-study variability in quantitative transporter expression data, the ratio of maximum and minimum abundance was calculated for each study and per individual transporter.
OATP1B3 protein expression in the liver tissue exhibited the greatest variability, resulting in 1.5-to 32-fold difference across individual studies. The within-study variability in hepatic tissue expression ranged from 3.3-to 6.6-fold for OATP1B1 and from 1.5-to 7.5-fold for OATP2B1. A maximum of 4.7-and 3.6-fold difference was observed in the reported OATP expression in SCHH and cryopreserved hepatocytes, respectively (based on 4-13 donors, Table 1 ).
Collated OATP transporter abundance data reported for liver tissue and hepatocytes in different formats exhibited neither normal distribution nor equal variances. As a consequence, a nonparametric Kruskal-Wallis one way analysis of variance (ANOVA) was conducted followed by a multiple comparison Mann-Whitney U-test as post-hoc analysis. The threshold level of significance was modified from 0.05 to 0.025 using Bonferroni correction due to the two pairwise comparisons performed on the same dataset in order to reduce the likelihood of false-positive results. Transporter abundance data were not statistically significantly different between liver tissue and in vitro cellular systems, with the exception of OATP2B1 expression in SCHH relative to liver tissue (Mann-Whitney U-test, p < 0.005) characterized with a moderate sample size effect (r = 0.29) (Fig. 1) .
Inter-study variability in OATP Abundance in Liver Tissue. Heterogeneity tests were performed to investigate inter-study variability in reported abundance data. Heterogeneity tests detected moderate (OATP1B1, I 2 ≈ 60%, p < 0.05) and high (OATP1B3 and OATP2B1, I 2 > 80%, p < 0.001) heterogeneity between data reported for liver tissue, as outlined in Table 2 . Heterogeneity tests were not achievable between studies reporting data in in vitro cellular systems, either due to small number of studies or lack of individual data. Due to non-normal distribution, hepatic tissue abundance data were compared applying the same non-parametric statistical analysis as the one used for the analysis of transporter expression in cellular systems relative to liver tissue. The threshold level of significance was modified from 0.05 to 0.0125 due to the four pairwise comparisons performed on the same dataset (Bonferroni correction). Hepatic tissue expression data showed statistically significant differences between studies and characterized with moderate (0.4) to high (0.7) sample size effects; different levels of significance are detailed in Table 2 and Fig. 2 .
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Investigation of Age-and Sex-Related Differences in Hepatic Tissue Expression Levels
of OATP Transporters. The distribution of hepatic tissue abundance data collated from three studies was non-normal based on the Kolmogorov-Smirnov test. As a result, non-parametric tests were applied to assess differences in expression levels between male and female subjects and against age. Statistically significant weak correlation was detected between expression levels of OATP1B1
and age of the human donors (Spearman correlation test, Rs = 0.33, p < 0.01, n = 80) (Fig. 4A ), whereas the correlation with age for OATP1B3 and OATP2B1 transporters was not significant (Spearman correlation test, Rs < 0.10, p > 0.05, n = 80, Supplemental Fig. 1 ). In addition, hepatic tissue expression levels were not significantly different between male (n = 44) and female (n = 36) subjects for any of the OATP transporters investigated (Mann-Whitney U-test, p > 0.05) (Fig. 4B ).
This article has not been copyedited and formatted. The final version may differ from this version. Gertz et al., 2013; Varma et al., 2013; Gertz et al., 2014; Jamei et al., 2014) ; however, the abundance of OATPs and other transporters is not adequately incorporated in the PBPK models as yet, primarily due to lack of data (Zamek- Gliszczynski et al., 2013; Galetin, 2014) . Despite emerging proteomic data, so far no systematic analysis of the differences in total membrane protein expression of OATP1B1, OATP1B3 and OATP2B1 reported in the liver tissue and cryopreserved hepatocytes has been performed. Following the inclusion criteria, 8 individual studies were considered herein; the number of individual samples used to quantify the transporters investigated ranged from 1 to 64. Significant moderate to high heterogeneity between studies was detected per individual transporter for the liver tissue abundance data. In contrast, the degree of heterogeneity could not be assessed in cellular systems as the number of studies was either too small and/or only the average expression data of investigated transporters was quoted.
The current analysis revealed marginal differences in OATP expression levels between liver tissue and cryopreserved hepatocytes in suspension, as the relative expression factors for all OATPs were <1.5-fold for this cellular system (Fig. 1, Table 2 ). In the case of SCHH, relative expression factor of up to 2.5-fold is required for OATP1B3 and OATP2B1, in contrast to OATP1B1 where the weighted mean protein expression of this transporter was comparable between liver tissue and SCHH (based on n = 5 samples). The current analysis revealed substantial differences in the extent of variability of OATP1B3 abundance data (1.5-to 32-fold within individual studies). This trend was also evident in the study with the largest sample size where OATP1B3 expression varied 8.8-fold in 64 subjects (Prasad et al., 2014) , in agreement with variability in OATP1B1 and OATP2B1 expression within the same study (up to 6.6-fold). In most of the studies, the extent of variability in protein expression exceeds the differences associated with the well-recognized genetic variations in the SLCO1B1 and SCLO1B3 genes encoding OATP1B1 and OATP1B3, respectively (Link et al., 2008; Niemi et al., 2011; Gong and Kim, 2013 
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The present meta-analysis investigated for the first time the correlation between OATP expression levels in the same individuals; this analysis was only performed for the liver tissue due to availability of data. The low and moderate correlations observed (Fig. 3) suggests limited dynamic coregulation of OATP transporters, as opposed to metabolizing enzymes (Achour et al., 2014) . By aggregating the abundance data reported in three studies, the analysis identified a significant but weak correlation of hepatic tissue expression levels of OATP1B1 with age of the human donors, as opposed to the findings reported by each individual selected study (Balogh et al., 2012; Prasad et al., 2014; Vildhede et al., 2014) . In addition, no differences in abundance data were apparent between male and female subjects, consistent with the outcomes of individual studies. This finding was in agreement with a recent meta-analysis of abundance data of drug-metabolizing P450 enzymes (Achour et al., 2014) .
There are several limitations to the analysis presented here that merit consideration when interpreting the findings. The first limitation is the relatively small number of eligible studies and also their sample size, which is in particular evident for data reported in SCHH. In addition, individual expression data of the selected OATP transporters were not quoted or extractable in some of the studies. Hence, average abundance data were incorporated in the analysis along individual data, lowering the statistical power of the analysis. In addition, most of the studies did not quantify the transporter expression levels in the liver tissue and cellular systems from the same donor. One exception is the study by where OATP abundance data were reported for the hepatocyte systems (SCHH and cryopreserved hepatocytes in suspension) prepared from the same donor; however, no corresponding expression data for the liver tissue were available. The mean expression of OATP1B1 and OATP2B1 from the five donors in Kimoto et al. study did not show a statistical difference between the two hepatocyte formats, with the exception of OATP1B3 which was significantly decreased in SCHH. These findings were partially in agreement with the outcomes of the meta-analysis, as no significant differences in expression levels of all OATP transporters investigated were detected between SCHH and cryopreserved hepatocytes in suspension (n = 17) (Fig. 1) . In addition, no expression data are currently available for cryopreserved hepatocytes in monolayer format highlighting the need for larger datasets to fully understand differences in transporter expression under differing culturing conditions, associated variability between in vitro systems and impact of these factors on transporter-mediated IVIVE. Finally, demographic information of the human This article has not been copyedited and formatted. The final version may differ from this version. However, considering that the abundance data were determined using the plasma membrane fraction, these two studies were excluded from the current analysis. Ohtsuki et al. (2012) reported higher expression of an ion transporter protein Na/K-ATPase (considered to be a basal membrane marker) in the crude total membrane fraction compared to the plasma membrane fraction obtained from the same liver samples (n = 17). However, a higher abundance should be expected, at least theoretically, in the plasma membrane fraction which is anticipated to be more transporter-enriched and functionally-pertinent. Arguably, losses due to plasma membrane preparation methods could be responsible for this contradiction, as highlighted recently (Harwood et al., 2014) . Plasma membrane may contain only a fraction of the total expressed transporter due to potential internalization reported for several transporter proteins (Bow et al., 2008; Kock et al., 2010; Choi et al., 2011) . In addition, impact of post-translational modifications on cell surface trafficking and expression of OATPs is still not well defined. For these reasons, it seemed more appropriate to use studies that quantified transporters in crude total membrane as opposed to plasma membrane.
Heterogeneity between studies highlighted in this analysis may be a consequence of methodological diversity and raises questions whether the differences in expression levels of OATP transporters may be due to the method of tissue procurement (organ donors vs. resections from diseased livers), tissue storage conditions (frozen vs. fresh tissue) and/or diversity in subject demographics. In addition, sample preparation, i.e., membrane fractionation methods, differences in LC-MS/MS protein quantification, selection of the standard peptide, variation in proteolytic digestion of membrane proteins and technical recovery may all contribute to the heterogeneity observed. Although there seemed to be an overall agreement between studies in the selection of internal standards and the use of proteolytic enzyme, differences were identified in the method of extraction of membrane fractions, the calibration process, proteolytic conditions and the type of quantification (details in This article has not been copyedited and formatted. The final version may differ from this version.
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Supplemental Table 2 ). Interestingly, Karlgren et al. (2012) and Vildhede et al. (2014) used a label free relative quantification method which does not use internal standards and requires no calibration.
In all the studies, the calibration process was carried out using light peptide standards of known concentrations with the exception of Ji et al. (2012) who used purified OATP proteins previously quantified by amino acid analysis. Calibration using protein standards is expected to improve the quality of the quantification process; however, this study only quantified one sample of cryopreserved hepatocytes which did not permit comparison with other data. The discussed technical and analytical differences may account for some of the inter-study variability identified here. It is, therefore, suggested that the interpretation of the heterogeneity noted in the current analysis cannot solely be 10.6 ± 4.6 4.8 5.9 ± 3.8 4.9 2.9 ± 1.3 1.5 4 (Balogh et al., 2012) 8.9 ± 3.7 3.3 6.5 ± 1.1 1.5 4.3 ± 0.9 1.6 5 7.2 -6.3 -4.0 -1 (Karlgren et al., 2012) 2.0 ± 0.9 6.6 1.1 ± 0.5 8.7 1.7 ± 0.6 6.0 64 (Prasad et al., 2014) 23.2 ± 9.4 3.7 3.2 ± 1.9 32 1.6 ± 1. 4.6 ± 1.4 3.0 1.7 ± 0.6 3.6 1.5 ± 0.5 3.6 13 3.4 -1.5 -1.8 -1 5.8 -5.8 -4.1 -1 2.4 ± 0.5 -0.9 ± 0.5 -1.7 ± 0. (Balogh et al., 2012) [2] [3] (Karlgren et al., 2012) [4] (Prasad et al., 2014) [5] (Vildhede et al., 2014) [6] [7] 
